Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ATBPD OTCMKTS:INVVY NASDAQ:RPTX NASDAQ:STTK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATBPDAntibe Therapeutics$0.00$2.64▼$3.50$1.21B0.5729,710 shsN/AINVVYIndivior$21.85-1.8%$21.85$14.76▼$35.50$3.01B0.353,825 shs8,100 shsRPTXRepare Therapeutics$2.65+0.8%$2.62$1.24▼$2.66$114.24M0.97516,093 shs1.22 million shsSTTKShattuck Labs$4.74+9.5%$6.28$0.71▼$8.33$363.47M1.08693,212 shs741,869 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATBPDAntibe Therapeutics0.00%0.00%0.00%0.00%0.00%INVVYIndivior0.00%0.00%0.00%0.00%0.00%RPTXRepare Therapeutics0.00%0.00%0.00%0.00%+82.76%STTKShattuck Labs-6.48%+1.41%-30.83%-28.31%+333.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATBPDAntibe Therapeutics$0.00$2.64▼$3.50$1.21B0.5729,710 shsN/AINVVYIndivior$21.85-1.8%$21.85$14.76▼$35.50$3.01B0.353,825 shs8,100 shsRPTXRepare Therapeutics$2.65+0.8%$2.62$1.24▼$2.66$114.24M0.97516,093 shs1.22 million shsSTTKShattuck Labs$4.74+9.5%$6.28$0.71▼$8.33$363.47M1.08693,212 shs741,869 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATBPDAntibe Therapeutics0.00%0.00%0.00%0.00%0.00%INVVYIndivior0.00%0.00%0.00%0.00%0.00%RPTXRepare Therapeutics0.00%0.00%0.00%0.00%+82.76%STTKShattuck Labs-6.48%+1.41%-30.83%-28.31%+333.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATBPDAntibe Therapeutics 0.00N/AN/AN/AINVVYIndivior 3.00Buy$50.00128.88% UpsideRPTXRepare Therapeutics 2.00Hold$3.0013.21% UpsideSTTKShattuck Labs 2.80Moderate Buy$11.00132.07% UpsideCurrent Analyst Ratings BreakdownLatest STTK, INVVY, ATBPD, and RPTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026STTKShattuck Labs Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $17.006/8/2026STTKShattuck Labs HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.006/5/2026STTKShattuck Labs Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform$7.006/5/2026STTKShattuck Labs CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$7.006/2/2026STTKShattuck Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/19/2026STTKShattuck Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/8/2026STTKShattuck Labs WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $11.004/27/2026STTKShattuck Labs Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight4/20/2026STTKShattuck Labs HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $18.00(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATBPDAntibe Therapeutics$7.51M0.00N/AN/A$0.10 per share0.00INVVYIndivior$791M3.81$1.15 per share18.94$1.45 per share15.07RPTXRepare Therapeutics$11.87M9.62N/AN/A$3.56 per share0.74STTKShattuck Labs$1M363.47N/AN/A$1.30 per share3.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATBPDAntibe Therapeutics-$14.54M-$0.60N/AN/AN/A-273.96%-150.49%-98.51%N/AINVVYIndivior$205M$1.0520.8112.00N/AN/AN/AN/AN/ARPTXRepare Therapeutics-$84.69M-$1.69N/AN/AN/AN/A-60.15%-52.24%N/ASTTKShattuck Labs-$48.81M-$0.63N/AN/AN/AN/A-60.73%-55.75%8/13/2026 (Estimated)Latest STTK, INVVY, ATBPD, and RPTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026STTKShattuck Labs-$0.14-$0.13+$0.01-$0.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATBPDAntibe TherapeuticsN/AN/AN/AN/AN/AINVVYIndiviorN/AN/AN/AN/AN/ARPTXRepare TherapeuticsN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATBPDAntibe TherapeuticsN/A5.975.42INVVYIndiviorN/AN/AN/ARPTXRepare TherapeuticsN/A10.7110.71STTKShattuck LabsN/A22.0722.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATBPDAntibe TherapeuticsN/AINVVYIndivior0.05%RPTXRepare Therapeutics85.09%STTKShattuck Labs58.74%Insider OwnershipCompanyInsider OwnershipATBPDAntibe TherapeuticsN/AINVVYIndiviorN/ARPTXRepare Therapeutics11.50%STTKShattuck Labs8.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATBPDAntibe Therapeutics47387.00 millionN/ANot OptionableINVVYIndivior800137.88 millionN/ANot OptionableRPTXRepare Therapeutics18043.11 million38.15 millionOptionableSTTKShattuck Labs10076.68 million69.94 millionOptionableSTTK, INVVY, ATBPD, and RPTX HeadlinesRecent News About These CompaniesShattuck Labs (NASDAQ:STTK) Upgraded at Wall Street ZenJune 13, 2026 | americanbankingnews.comShattuck Labs (NASDAQ:STTK) Director Clay Siegall Buys 62,500 SharesJune 12, 2026 | insidertrades.comShattuck Labs Prices Upsized Public Equity and Warrant OfferingJune 11, 2026 | tipranks.comShattuck Labs: "Hold" On Phase 1 SL-325 Data And Next Stage Of DevelopmentJune 10, 2026 | seekingalpha.comShattuck Labs drops 6%, prices $75M share raise at $4 per shareJune 10, 2026 | msn.comWhat's going on with Shattuck Labs stock Wednesday?June 10, 2026 | msn.comShattuck Labs, Inc. Announces Pricing of $75 Million Public OfferingJune 9, 2026 | globenewswire.comH.C. Wainwright Sticks to Its Buy Rating for Shattuck Labs (STTK)June 9, 2026 | theglobeandmail.comShattuck Labs launches proposed public offering of common stockJune 9, 2026 | msn.comShattuck Labs, Inc. Announces Public Offering of Common Stock and Pre-Funded WarrantsJune 9, 2026 | quiverquant.comQShattuck Labs, Inc. Announces Proposed Public OfferingJune 9, 2026 | globenewswire.comShattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial UpdateJune 9, 2026 | globenewswire.comShattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update TranscriptJune 8, 2026 | seekingalpha.comWhy Is Shattuck Labs Stock Trading Lower On Monday?June 8, 2026 | benzinga.comShattuck Labs Reports Promising Phase 1 Results for SL-325, a Potential First-in-Class DR3 Blocking Antibody for Crohn's DiseaseJune 8, 2026 | quiverquant.comQShattuck Labs Announces Phase 1 Results for SL-325June 8, 2026 | globenewswire.comShattuck Labs Shareholders Approve Directors, Compensation, Governance MeasuresJune 6, 2026 | theglobeandmail.comShattuck Labs to Present Phase 1 Clinical Data for SL-325 and Pipeline Update on June 8, 2026June 5, 2026 | quiverquant.comQShattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8June 5, 2026 | markets.businessinsider.comShattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8June 5, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTTK, INVVY, ATBPD, and RPTX Company DescriptionsAntibe Therapeutics OTCMKTS:ATBPDAntibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.Indivior OTCMKTS:INVVY$21.85 -0.40 (-1.82%) As of 06/9/2023Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.Repare Therapeutics NASDAQ:RPTXRepare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.Shattuck Labs NASDAQ:STTK$4.74 +0.41 (+9.47%) Closing price 04:00 PM EasternExtended Trading$4.86 +0.12 (+2.45%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta and Cloud Computing: Real Potential, or a Shot in the Dark? Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Fox Captures The Living Room With $22B Roku Buy Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan Microsoft’s Xbox Problem Is Bigger Than a Console War Could a Tesla-SpaceX Merger Be Closer Than Investors Think? After SpaceX, Amazon Could Be The Next Best Space Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
